Summary B-cell high-grade lymphomas are heterogeneous in terms of histology, clinical presentation, treatment response and prognosis. As bcl-2 and p53 gene deregulations are frequencly involved in several types of lymphoid malignancies, we aimed our investigation at the study of the relation between bcl-2 and p53 expression and survival probability in a group of 119 patients with B-cell high-grade lymphoma. These were obtained from the Virgen de la Salud Hospital, Toledo, Spain (73 cases), John Radcliffe Hospital, Oxford, UK (31 cases), and the Istituto Nazionale dei Tumori, Milan, Italy (15 cases). The relation between bcl-2 protein expression and survival was small, depending on the primary localisation of the tumour (in lymph node of mucosae), and lacked a significant correlation with overall survival. In contrast with this, p53 expression was related to survival probability in our series, this relation being both significant and independent of histological diagnosis. p53-positive patients showed a sudden decrease in life expectancy in the first months after diagnosis. Multivariant regression analysis confirmed that the only parameters significantly related with survival were extranodal origin, which is associated with a better prognosis, and p53 expression, which indicates a poor prognosis. Simultaneous expression of bcl-2 and p53 was associated with a poorer prognosis than p53 alone. This is particularly significant for large B-cell lymphomas presenting in lymph nodes. The cumulative poor effect of both p53 and bcl-2 in large B-cell lymphomas, which is more significant in nodal tumours, could confirm the existence of a multistep genetic deregulation in non-Hodgkin's lymphoma. This indicates that the genetic mechanisms controlling apoptosis and their disregulation are critical steps in the progression of lymphomas.
Large-cell lymphomas (LCL) are heterogeneous in terms of histology, clinical presentation, treatment response and prognosis. Although some clinical parameters (age, stage, histological diagnosis, lactate dehydrogenase, tumour burden) may allow survival time to be predicted, the genetic and molecular basis of the progression of the disease and its response to chemotherapy have yet to be elucidated (Velasquez et al., 1989; Coiffier et al., 1991) . Although the 14;18 translocation has been found in 10-25% of LCL, and 8;14 translocation in 10% of LCL and 90% of Burkitt's lymphomas, specific chromosomal changes have not yet been found in most cases of B-cell high-grade lymphoma (Aisenberg et al., 1988; Raghoebier et al., 1991) . The 14;18 translocation juxtaposes the immunoglobulin heavy-chain gene onto the bcl-2 oncogene on chromosome 18, giving rise to activation of the bcl-2 gene, with increased production of mRNA and protein (Seto et al., 1988) . bcl-2 protein has been shown to induce cell survival by blocking programmed cellular death in transfected cell lines (Hockenberry et al., 1990) . bcl-2 expression can be independent of t(14;18) (Pezzella et al., 1990) , it being possible to induce bcl-2 expression by latent Epstein-Barr virus genes (Henderson et al., 1991; Finke et al., 1992) . bcl-2 expression has been found in a high percentage of large B-cell non-Hodgkin lymphomas (Pezzella et al., 1990; Villuendas et al., 1991; Zutter et al., 1991) .
p53 is a suppressor gene, involved in the transcription of genes that negatively control cell proliferation. Protein detection by immunocytochemistry has been related to gene mutation, which stabilises the protein and prevents its degradation. However, further studies have confirmed that activated lymphoid cells may express p53, expression being dependent on cell cycle phase (M. Sanchez-Beato, submitted). p53 mutations have been described in Burkitt's lymphoma (Farrell et al., 1991; Gaidano et al., 1991; Wiman et al., 1991) , and adult T-cell leukaemia/lymphoma (ATLL) (Ceserman et al., 1992 ) but p53 protein detection has been reported in other different types of B-cell high-grade lymphoma (Doglioni et al., 1991; Villuendas et al., 1992; Pezzella et al., 1993) . A recent study relates p53 mutation to disease progression in B-cell lymphoma (Ichikawa et al., 1992) .
Both p53 and bcl-2 genes have been described as related to the genetic control of apoptosis, or programmed cell death (Hockenberry et al., 1990; Clarke et al., 1993; Fritsche et al., 1993; Hall et al., 1993; Lowe et al., 1993) . The aim of this investigation was the study of both bcl-2 and p53 expression, in relation to survival in B-cell high-grade non-Hodgkin lymphomas (NHLs).
Materials and methods
Tissue samples Fresh frozen tissue samples from 119 patients with B-cell high-grade lymphoma were obtained through the routine histopathological services of the Virgen de la Salud Hospital, Toledo, Spain (73 cases), John Radcliffe Hospital, Oxford, UK (31 cases), and Istituto Nazionale dei Tumori, Milan, Italy (15 cases). Diagnosis was based on examination of paraffin-embedded material stained by haematoxylin and eosin, and on the immunostaining of frozen sections according to routine techniques. Eighty-eight cases were classified as nodal diffuse large B-cell lymphoma (centroblastic or immunoblastic); 25 as mucosa-associated lymphoid tissue (MALT) large B-cell lymphoma in gastrointestinal tract or lung, without lymph node infiltration beyond regional lymphadenopathies; and 10 as Burkitt's lymphoma. Classification criteria were used according to the Kiel update classification (Lennert & Feller, 1990 
Immunohistochemistry
Frozen sections were immunostained using the alkaline phosphatase-anti-alkaline phosphatase (APAAP) method (Cordell et al., 1984) , with the anti-bcl-2 monoclonal antibody bcl-2 100 (Pezzella et al., 1990) raised to a synthetic peptide. For p53 detection the anti-p53 monoclonal antibody PAb 1801 was used. This specifically detects human wild-type and mutant p53 (Banks et al., 1986) , recognising the N-terminal epitope of the protein.
Positive staining of small lymphocytes for bcl-2 provided an internal control for bcl-2 staining. Cases in which small lymphocytes were bcl-2 negative were excluded. For p53, simultaneous staining of known p53+ cases was employed. The incubation of parallel slides omitting the first antibody was performed as a negative control.
Statistical analysis Actuarial survival curves were plotted using the Kaplan and Meier (1958) method. Statistical significance was calculated using the log-rank test (Peto et al., 1975) for univariate analysis. The Cox (1972) Tables I to  IV. bcl-2 protein expression Immunostaining for bcl-2 was performed on 115 cases, the results of which are given in Table I . Two patterns of staining were observed: in 64 cases the great majority of neoplastic cells were bcl-2 positive in cytoplasm, whereas in the remaining 51 cases lymphomatous cells were negative. As is shown in Tables I and II, the expression of bcl-2 is distributed according to histological classification, being frequent in nodal and rare in mucosal large B-cell lymphomas (P < 0.001). The survival curve for bcl-2-positive cases shows that patients with these tumours have a progressive decrease in life expectancy, without a definite plateau (Figure 1) . Nevertheless, bcl-2 expression does not appear to be related to survival in a statistically significant way over the entire group of B-cell high-grade lymphomas (P = 0.143) (Table III) (Table IV) , independently of the other factors analysed (P = 0.019). In a separate assay, the impact of simultaneous p53 and bcl-2 expression was assessed, the relative risk being equivalent to the addition of p53 and bcl-2 relative risks. The distribution of both bcl-2 and p53 proteins in reactive lymph nodes and lymphomas has already been described (Pezzella et al., 1990 (Pezzella et al., , 1993 Villuendas et al., 1991 Villuendas et al., , 1992 . The results are similar to those found in this series, in which bcl-2 expression is more frequently detected in large B-cell lymphomas of nodal origin, and rarely in cases of Burkitt and MALT lymphoma.
Discussion
Deregulation of the bcl-2 gene represents a primary pathogenic event in the generation of some types of lymphoma, mainly those associated with a 14;18 translocation. bcl-2 activation could condition progression of a neoplasia through different mechanisms. bcl-2 expression in cell lines can confer a survival advantage on tumoral cells, through the inhibition of apoptosis or programmed cellular death (Hockenberry et al., 1990) . It has also been suggested that bcl-2 activation, through cooperation with c-myc or other oncogenes, may lead to drug resistance by blocking apoptosis (Fanidi et al., 1992) .
The prognostic significance of bcl-2 expression has already been explored in follicular CB-CC lymphoma, in which bcl-2-positive and -negative tumours have a similar prognosis (Pezzella et al., 1992) . In our series, patients with bcl-2+ tumours showed a progressive decrease in survival probability, with some late relapses being found. This is different from findings in cases of bcl-2-negative high-grade B-cell lymphomas, which show a definite plateau after an initial fall in survival probability. However, the relation between bcl-2 protein expression and survival seems to be small, depending on the diagnosis (nodal or MALT). It also lacks a significant Figure 3 Relation between bcl-2 and p53 combined expression and survival probability. Comparison of cases with simultaneous expression of both markers vs cases with only one or neither. 0, bcl-2+, p53+; x, bcl-2-l', p53-/+. relationship with overall survival. These results failed to confirm those obtained by Yunis et al. (1989) , which suggest that in follicular lymphomas with a large-cell component the presence of a (14;18) translocation is associated with a poor prognosis. However, differences in the selection of cases and in the technique for demonstrating bcl-2 activation may explain some of the differences found.
p53 expression in this group of patients is found in similar percentages in lymphomas of mucosa and nodal origin, and is more frequent in Burkitt cases. The relation between p53 expression and overall survival in our series is significant, independently of histological diagnosis, and is perhaps related to treatment failure, since p53-positive patients show a sudden decrease in life expectancy during the first months after diagnosis. Multivariant regression analysis findings are in agreement with these results. They confirm that the only parameters significantly related with survival are extranodal origin, which is associated with a better prognosis, and p53 expression, which indicates a poor prognosis. The relationship between p53 expression and low survival rates has also been found in other types of tumours (Thor et al., 1992; Visakorpi et al., 1992) . This has been suggested for lymphomas (Levine et al., 1988; Cabanillas et al., 1989; Schouten et al., 1990; Rodriguez et al., 1991) , based on cytogenetic studies. Significantly, Cabanillas et al. (1989) described a strikingly high rate of refractoriness to chemotherapy in patients with chromosome 17 alterations. This is similar to the early strong decrease in life expectancy for the p53+ patients in our series. An association between multidrug resistance protein (MDR) and p53 protein has in fact been proposed, since mutant p53 may stimulate MDR1 promoter, and wild-type p53 could exert specific repression (Chin et al., 1992) . This MDR activation could explain the absence of chemotherapeutic response in p53 + patients. Recent findings about the role of p53 gene suggest new possibilities for explaining the speedier progression of p53+ tumours. Different groups have shown p53 levels to increase after genotoxic injury, this high level of p53 protein being related to the capacity of cells with DNA damage to undergo apoptosis (Clarke et al., 1993; Fritsche et al., 1993; Hall et al., 1993; Lowe et al., 1993) . This may imply that cells with inactivation of one or both p53 alleles (consequently lacking this mechanism of programmed cell death induction) could have a survival advantage over those without p53 alterations. The range of p53 expression detected in this series of NHLs may be a common final consequence of different ways of genetic inactivation. In fact, p53 detection by immunohistological techniques has been described as the consequence of protein stabilisation dependent on a conformational change from wild-type to mutant-type protein (Milner & Medcalf, 1991) . While the wild-type p53 protein has a suppressor role in the control of the cell cycle, mutant p53 protein may have the opposite effect, inducing cell growth (Finlay et al., 1988; Hinds et al., 1989; Lane & Benchimol, 1990) . Mutation of the p53 gene or conformational change in the p53 protein secondary to other causes may constitute a key step in some lymphomas, allowing further tumour expansion, as has been found in other human tumours (Sidransky et al., 1992) .
The combined expression of bcl-2 and p53 identifies tumours with a poorer prognosis than those expressing p53 only. This is particularly significant for cases of large B-cell lymphoma presenting in lymph node. This poorer prognosis seems to be dependent on the accumulation of both bcl-2 and p53 expression rather than the interaction between them. However, comparative analysis between the groups of bcl-2+, p53+ lymphomas vs bcl-2-, p53+ is difficult because of the small number of cases included in both groups and the short follow-up of the bcl-2-, p53+ group. This prevents the detection of significant differences. A longer follow-up of a larger group of lymphoma patients could indicate the specific impact of each marker on survival.
The cumulative poor effect of both p53 and bcl-2 in large B-cell lymphomas, which is more significant in nodal tumours, could confirm the existence of multiple gene deregulation in non-Hodgkin's lymphoma. This would take place in a multistep pattern similar to that described in colorectal cancer (Fearon & Vogelstein, 1990 ) and would address the genetic mechanisms of apoptosis control and their disregulation as critical steps in the progression of tumours.
p53 expression could be tested for in NHLs, as a cheap and reproducible way of identifying patients with a poor prognosis. p53+ tumours could be candidates for more intensive therapy, or different therapeutic approaches.
